Back to top
more

Fulcrum Therapeutics (FULC)

(Real Time Quote from BATS)

$3.55 USD

3.55
315,141

+0.11 (3.20%)

Updated Sep 19, 2024 11:40 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (84 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Merck's Keytruda Obtains its First FDA Approval for Mesothelioma

by Zacks Equity Research

The FDA approves MRK's Keytruda for first-line treatment of malignant pleural mesothelioma. This marks Keytruda's first approval for the given indication.

Zoetis Stock Rises 15% in 3 Months: Time to Add to Your Portfolio?

by Zacks Equity Research

ZTS' innovative pet care products, along with efforts to expand the business, are expected to fuel significant growth in the future.

RCKT Completes Enrollment in Rare Heart Disease Study, Stock Rises

by Zacks Equity Research

Rocket completes enrollment of patients in a pivotal phase II study evaluating RP-A501 for treating male patients with Danon disease.

Zentalis Stock Up as FDA Lifts Partial Hold on Cancer Drug Studies

by Zacks Equity Research

ZNTL stock gains as the FDA lifts clinical hold on studies of its lead candidate, azenosertib, which is being developed for different cancer indications.

Incyte Announces Promising New Data on Oncology Candidate at ESMO

by Zacks Equity Research

INCY's INCB123667 data show the candidate's potential as a differentiated treatment option for cancers with increased cyclin E1 activity, amplification and/or overexpression in cells predictive of CDK2 dependency.

Here's Why Investors Should Invest in Arcturus Stock Now

by Zacks Equity Research

Here, we are discussing some reasons why investing in ARCT stock now may turn out to be a prudent move.

Fulcrum Therapeutics (FULC) Loses -65.58% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

The heavy selling pressure might have exhausted for Fulcrum Therapeutics (FULC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study

by Zacks Equity Research

Immuneering stock soars 41% as lead drug combo regimen shows superior initial efficacy in the first-line treatment of pancreatic cancer in a mid-stage study.

Gilead Stock Rises as HIV Prevention Injection Meets Study Goals

by Zacks Equity Research

GILD reports the success of its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, in a second late-stage study for the prevention of HIV.

FULC Stock Falls as Muscle Disorder Study Misses Primary Goal

by Zacks Equity Research

The phase III REACH study evaluating Fulcrum's losmapimod for treating facioscapulohumeral muscular dystrophy fails to meet the primary endpoint.

Aura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer Study

by Zacks Equity Research

AURA stock up as lead candidate shows tumor control and visual acuity preservation abilities in eye cancer patients over 12 months of treatment.

GSK's HSV Vaccine Study Fails to Meet Primary Efficacy Goal

by Zacks Equity Research

The phase I/II proof-of-concept study evaluating GSK's herpes simplex virus vaccine candidate, GSK3943104, fails to meet the primary efficacy objective.

FDA Grants Orphan Drug Tag to AGIO's Tebapivat for Rare Cancer

by Zacks Equity Research

The FDA bestows an orphan drug designation to Agios' PK activator, tebapivat, for treating myelodysplastic syndromes.

ITRM Posts Updates From FDA Advisory Meeting for UTI Drug, Stock Down

by Zacks Equity Research

Iterum provides updates from the FDA's Antimicrobial Drugs Advisory Committee meeting on its NDA for oral sulopenem to treat adult women with uUTI.

VRDN Stock Soars as Eye Disorder Study Meets Primary Endpoints

by Zacks Equity Research

The phase III THRIVE study evaluating Viridian's veligrotug for treating active thyroid eye disease meets all primary and secondary endpoints.

Corvus Stock Up on Initiation of Phase III Lymphoma Study on Lead Drug

by Zacks Equity Research

CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell lymphoma.

Xencor Stock Gains 23% on Encouraging Pipeline Advancements

by Zacks Equity Research

XNCR moves four new XmAb drug development programs for autoimmune diseases. It also provided favorable updates for two of its oncology drug candidates.

Summit Hits Record High on Lung Cancer Drug Topping Merck's Keytruda

by Zacks Equity Research

Data from a late-stage study shows that SMMT's experimental antibody beat Keytruda in a head-to-head setting in treating certain patients with NSCLC.

RZLT Stock Up as FDA Lifts Clinical Holds on Rare Disease Study

by Zacks Equity Research

The FDA removes the partial clinical holds on Rezolute's phase III study evaluating RZ358 for treating congenital hyperinsulinism.

Rocket Stock Down More Than 30% in Past Six Months: Here's Why

by Zacks Equity Research

The recent regulatory setbacks related to RCKT's pipeline candidate, Kresladi (marnetegragene autotemcel) weigh heavily on the stock.

IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab

by Zacks Equity Research

Immunovant stock rises on mid-stage study data of batoclimab for Graves' Disease, showing superior efficacy compared to anti-thyroid drug therapy options.

Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient

by Zacks Equity Research

HOTH stock soars on superior efficacy data from the first patient treated with the lead candidate, HT-001, suffering from EGFRI-related skin toxicities.

Novartis to License VYGR's Capsid for Gene Therapy in Neurology

by Zacks Equity Research

NVS has decided to license a novel capsid generated from Voyager's TRACER platform for use in a gene therapy program against an undisclosed rare neurologic disease target.

FDA Accepts AXSM's NDA Resubmission for Migraine Drug, Stock Up

by Zacks Equity Research

The FDA accepts Axsome's resubmission of the NDA for AXS-07 for the acute treatment of migraine. A decision is due on Jan. 31, 2025. Shares rise.

BioMarin Posts '27 Biz View, Outlines Growth Plans for Next 10 Years

by Zacks Equity Research

BMRN divulges ambitious plans for business growth over the next 10 years. It expects yearly sales to grow at a mid-teen rate through 2034.